Get the Stockscreener App
0.855
16.33%
0.12
Avenue Therapeutics Inc stock is traded at $0.855, with a volume of 30,119.
It is up +16.33% in the last 24 hours and down -70.96% over the past month.
See More
Previous Close:
$0.735
Open:
$0.85
24h Volume:
30,119
Relative Volume:
30.45
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-0.2244
EPS:
-3.81
Net Cash Flow:
$-12.45M
1W Performance:
+16.33%
1M Performance:
-70.96%
6M Performance:
-83.79%
1Y Performance:
-96.88%
1-Day Range:
$0.75
$0.90
1-Week Range:
$0.75
$0.90
52-Week Range:
$0.5231
$0.90
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare ATXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
0.855 | 0 | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Avenue Therapeutics Inc Stock (ATXI) Latest News
7 Biotech Stocks Trading At 52-Week HighsCan The Rally Continue? - RTTNews
Beam Therapeutics (NASDAQ:BEAM) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Nasdaq Compliance and Long-Term Viability of Society Pass (SOPA) - AInvest
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Dietary Changes Could Provide a Therapeutic Avenue for Brain Cancer | Newswise - Newswise
Coya Therapeutics to Participate at Upcoming September 2025 Investor Conferences - biospace.com
Coya Therapeutics to Participate at Upcoming September Investor Conferences - Stock Titan
How to escape a deep drawdown in Bicara Therapeutics Inc.Weekly Investment Report & Entry Point Strategy Guides - Newser
FBIO In FocusWill CUTX-101 Make History As The First FDA-Approved Menkes Disease Therapy? - RTTNews
Plus Therapeutics Inc. stock trend forecastPortfolio Return Summary & Fast Gaining Stock Strategy Reports - Newser
Abeona Therapeutics to expand in Midtown - NEOtrans
Applied Therapeutics Inc. (NASDAQ:APLT) Receives $6.10 Average PT from Analysts - MarketBeat
Has Anika Therapeutics Inc. formed a bullish divergenceJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - Newser
Will Galectin Therapeutics Inc. stock recover after recent dropJuly 2025 Breakouts & High Conviction Trade Alerts - Newser
Avenue Therapeutics Reports Positive Earnings Amid Challenges - TipRanks
North American Morning Briefing : Stock Futures -2- - MarketScreener
Should you wait for a breakout in Plus Therapeutics Inc.Quarterly Portfolio Report & Real-Time Buy Zone Alerts - Newser
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN
XTX Topco Ltd Buys 68,245 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com Canada
Abeona Therapeutics Amends Loan Agreement with Avenue - The Globe and Mail
Stoke Therapeutics Inc. Stock Analysis and ForecastFree Investment Risk Control - jammulinksnews.com
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment - Investing.com
Postoperative Pain Management Market to Expand Significantly - openPR.com
Why Acrivon Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
112-employee biotech leaves Cambridge HQ for Watertown - The Business Journals
AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion - The Wall Street Journal
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel (NASDAQ:TGTX) - Seeking Alpha
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha
656 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Park Avenue Securities LLC - Defense World
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 BillionWSJ - The Wall Street Journal
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - StreetInsider
Park Avenue Securities LLC Invests $259,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Park Avenue Securities LLC - Defense World
Yousif Capital Management LLC Has $1.99 Million Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Up 156.3% in May - Defense World
Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen - Defense World
NBC Securities Inc. Takes $31,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Cut to Sell at Wall Street Zen - Defense World
Park Avenue Securities LLC Has $713,000 Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Rhumbline Advisers Reduces Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Safety scares and trial misses drag down neuro biotechs into Q2 - BioWorld MedTech
Autolus Therapeutics’ (AUTL) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Park Avenue Securities LLC Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
NBC Securities Inc. Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stake Boosted by Millennium Management LLC - Defense World
Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.57%
Cap:
|
Volume (24h):